Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients
| Autor: | Neda Alrawashdh, Ali McBride, Ivo Abraham, Karen MacDonald |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Filgrastim Cyclophosphamide Breast Neoplasms Medicare Drug Costs Health Services Accessibility Polyethylene Glycols chemistry.chemical_compound Breast cancer Cost Savings Trastuzumab Internal medicine medicine Humans Computer Simulation Biosimilar Pharmaceuticals Aged Drug Substitution business.industry General Medicine Middle Aged medicine.disease United States Carboplatin Models Economic chemistry Docetaxel Expanded access Female business Pegfilgrastim Febrile neutropenia medicine.drug |
| Zdroj: | Future Oncology. 18:363-373 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Lay abstract Pegfilgrastim is used to prevent low white blood cell count in patients receiving chemotherapy. Comparable to a generic version of a drug, a biosimilar is a follow-on version of a biologic treatment. We calculated the savings from using biosimilar pegfilgrastim in a hypothetical group of 20,000 patients with breast cancer receiving chemotherapy with AC (doxorubicin/cyclophosphamide). We then computed the number of additional doses of AC chemotherapy that could be purchased with those savings. We did the same for a group of 5000 HER2+ breast cancer patients treated with TCH (docetaxel/carboplatin/trastuzumab). Using biosimilar pegfilgrastim could save $1,083 per patient per cycle. If all patients were treated with biosimilar pegfilgrastim over six cycles, $129.9 million could be saved in the AC group and $32.5 million in the TCH group. This could provide 220,468 additional AC doses and 6981 TCH doses. Biosimilar pegfilgrastim can generate significant savings. These savings can be used to provide additional patients with chemotherapy cost-free. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|